What is Apidra Vial?
Apidra is an insulin glulisine manufactured by Sanofi-Aventis. Apidra vial is made from a non-pathogenic strain of escherichia coli and differs from human insulin by substitution of lysine instead of aspargine in the B3 and glutamic acid instead of lysine at the B29 position.
Apidra vial contains 10mL or 1000 units each vial. It is made in colorless glass with an aluminum cap, tear-off lid, and inserted rubber gasket.
How to Take It?
Apidra vials can be used to refill external insulin infusion pumps. It should be taken subcutaneously 15 minutes before meals or within 20 minutes after meals. Rotation of the site of administration should be applied between the abdomen, thighs, and upper arms to avoid skin irritation. Injection in the abdomen is slightly faster to effect than the other sites and make sure to avoid muscles and veins. Apidra is a “bolus insulin” as it gives the patients high levels of insulin in a short period of time and it can be sometimes administered with a long-acting “basal-insulin” like insulin glargine, insulin detemir, and insulin degludac. The combination of basal and bolus insulin is often used to copy the production of endogenous insulin.
The doctor will determine the correct dose for each patient who will be using the Apidra vial. The doctor will base this on the patient’s blood sugar tests and lifestyle.
Get medical help if the Apidra vial will cause shortness of breath, fast heartbeat, swelling of face and throat, and extreme drowsiness. Hypoglycemia or low blood sugar, hypokalemia or low potassium, severe allergic reaction, and heart failure are serious side effects that can lead the patient to death. Common side effects of Apidra vials are weight gain, itching, swelling, lipodystrophy (skin thickening), and hypoglycemia.
Warnings, Precautions, and Contraindications
Ensure that the patient is not allergic to insulin glulisine or any other ingredients of the Apidra vial. Closely monitor if the patient will have hypoglycemia. Let the physician know if the patient is pregnant, or has liver or kidney problems so the dose should be adjusted by the physician.
Apidra can cause seizures, brain damage, or unconsciousness in hypoglycemic patients. Hypokalemia may cause respiratory paralysis. Anaphylaxis is a life-threatening hypersensitivity reaction in patients.
Keep Apidra vial in a refrigerator below 77°F (25°C) and away from direct heat and light. Throw away opened vial after 28 days after the first use.